Since peaking at $40, Acadia Pharmaceuticals (ACAD) is selling-off steadily. Biotech stocks are out of favor and there is nothing investors can do to stop the negative sentiment. Waiting and watching seems the most prudent move. Sales of Nuplazid did not ‘wow’ investors. Buy the dip? Buying the dip seems like a move value investors should take with ACAD. But waiting is a better idea. $ACAD, ACADIA Pharmaceuticals Inc. / D Until the selling pressure for the entire sector lightens up, ACAD could have more downside. The question is what entry price gives investors the best risk/return. Long-term, the market for Nuplazid is growing. The drug has strong indications and as developments progress, ACAD’s deep value will only widen. ACAD has 4 clinical trials for the drug. A fifth study will start this summer. Takeaway ACAD’s stock will rebound. The stock is oversold. An entry price at $25 is preferred but buyers may be accumulating the stock at current ($27.85) levels already.